AI assistant
Crinetics Pharmaceuticals, Inc. — Director's Dealing 2020
Jul 17, 2020
31156_dirs_2020-07-17_a8a15c46-0c86-4ed5-9c63-ab82b1bfa58c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2020-07-15
Reporting Person: Struthers Richard Scott (Director, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-07-15 | Common stock | S | 17500 | $15.2984 | Disposed | 908305 | Indirect |
| 2020-07-16 | Common stock | S | 17500 | $14.4633 | Disposed | 890805 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 100000 | Indirect |
| Common stock | 100000 | Indirect |
| Common Stock | 100000 | Indirect |
Footnotes
F1: Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $14.95 and $15.76 per share. Information on the exact number of shares sold at each price can be obtained from the issuer upon request.
F2: Represents the weighted average sale price for the entire number of shares sold. The actual sales prices range between $14.10 and $15.34 per share. Information on the exact number of shares sold at each price can be obtained from the issuer upon request.